Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) Short Interest Update

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 286,000 shares, a decline of 47.4% from the February 28th total of 543,400 shares. Currently, 4.3% of the shares of the company are short sold. Based on an average daily volume of 846,100 shares, the short-interest ratio is currently 0.3 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Bullfrog AI in the fourth quarter valued at about $30,000. Geode Capital Management LLC raised its stake in Bullfrog AI by 31.0% in the 4th quarter. Geode Capital Management LLC now owns 47,093 shares of the company’s stock worth $94,000 after purchasing an additional 11,140 shares in the last quarter. Finally, Two Sigma Securities LLC bought a new stake in Bullfrog AI in the 4th quarter valued at about $41,000. 0.96% of the stock is owned by institutional investors and hedge funds.

Bullfrog AI Stock Down 6.1 %

Shares of BFRG traded down $0.11 during trading hours on Friday, hitting $1.70. The company had a trading volume of 221,149 shares, compared to its average volume of 320,183. The firm has a market cap of $16.01 million, a price-to-earnings ratio of -2.00 and a beta of 0.32. The business has a fifty day moving average of $2.37 and a 200-day moving average of $2.37. Bullfrog AI has a 12 month low of $1.43 and a 12 month high of $4.84.

Bullfrog AI (NASDAQ:BFRG) last issued its quarterly earnings data on Friday, March 14th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Bullfrog AI Company Profile

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.